Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented ...
The Reporter

Signant Health Announces Launch of eCOA Acceleration Program & Remote Assessment Capabilities for CNS Studies

PHILADELPHIA, June 29, 2021 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, today announced a new acceleration program that reduces study setup timelines ...
Business Wire

Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and ...

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience ...

Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of ...

CNW/ -- (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient ...
ascopubs.org

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...